Manufacturers submit marketing authorisation application for omburtamab to the European Medicines Agency for

The application is for use in paediatric patients with central nervous system/ leptomeningeal metastasis from neuroblastoma. Omburtamab is a monoclonal antibody that targets B7-H3 and is radiolabelled before intraventricular administration.

Biospace Inc.